Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2015

01-03-2015 | Endocrine Tumors

Preventing Postoperative Hypocalcemia in Patients with Graves Disease: A Prospective Study

Authors: Sarah C. Oltmann, MD, Andrew V. Brekke, David F. Schneider, MD, MS, Sarah C. Schaefer, ANP-BC, Herbert Chen, MD, Rebecca S. Sippel, MD

Published in: Annals of Surgical Oncology | Issue 3/2015

Login to get access

Abstract

Background

Hypocalcemia occurs after total thyroidectomy (TT) for Graves disease via parathyroid injury and/or from increased bone turnover. Current management is to supplement calcium after surgery. This study evaluates the impact of preoperative calcium supplementation on hypocalcemia after Graves TT.

Methods

A prospective study of patients with Graves disease undergoing TT was performed. Patients with Graves disease managed over a 9-month period took 1 g of calcium carbonate (CC) three times a day for 2 weeks before TT. Those managed the previous year without supplementation served as historic controls. Age-, gender-, and thyroid weight-matched, non-Graves TT patients were procedure controls. Patient demographics, postoperative laboratory values, complaints, and medications were reviewed. Parathyroid hormone (PTH)-based postoperative protocols dictated postoperative CC and calcitriol use.

Results

Forty-five patients with Graves disease were treated with CC before TT, and 38 patients with Graves disease were not. Forty control subjects without Graves disease were identified. Age, gender, and thyroid weight were comparable. Preoperative calcium and PTH levels were equivalent. PTH values immediately after surgery, at postoperative day 1, and at 2-week follow-up were equivalent. Postoperative use of scheduled CC (p = 0.10) and calcitriol (p = 0.60) was similar. Postoperatively, patients with untreated Graves disease had lower serum calcium levels than pretreated patients with Graves disease or control subjects without Graves disease (8.3 mg/dL vs. 8.6 vs. 8.6, p = 0.05). Complaints of numbness and tingling were more common in nontreated Graves disease (26 %) than in pretreated Graves disease (9 %) or in control subjects without Graves disease (10 %, p < 0.05).

Conclusions

Calcium supplementation before TT for Graves disease significantly reduced biochemical and symptomatic postoperative hypocalcemia. Preoperative calcium supplementation is a simple treatment that can reduce symptoms of hypocalcemia after Graves TT.
Literature
1.
Hallgrimsson P, Nordenstrom E, Bergenfelz A, Almquist M. Hypocalcaemia after total thyroidectomy for Graves’ disease and for benign atoxic multinodular goitre. Langenbecks Arch Surg. 2012;397:1133–7.PubMedCrossRef
2.
Grodski S, Lundgren CI, Sidhu S, Sywak M, Delbridge L. Postoperative PTH measurement facilitates day 1 discharge after total thyroidectomy. Clin Endocrinol. 2009;70:322–5.CrossRef
3.
Sywak MS, Palazzo FF, Yeh M, et al. Parathyroid hormone assay predicts hypocalcaemia after total thyroidectomy. ANZ J Surg. 2007;77:667–70.PubMedCrossRef
4.
McCullough M, Weber C, Leong C, Sharma J. Safety, efficacy, and cost savings of single parathyroid hormone measurement for risk stratification after total thyroidectomy. Am Surg. 2013;79:768–74.PubMed
5.
Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery. 2003;133:180–5.PubMedCrossRef
6.
Wang TS, Cheung K, Roman SA, Sosa JA. To supplement or not to supplement: a cost-utility analysis of calcium and vitamin D repletion in patients after thyroidectomy. Ann Surg Oncol. 2011;18:1293–9.PubMedCrossRef
7.
Mazeh H, Khan Q, Schneider DF, Schaefer S, Sippel RS, Chen H. Same-day thyroidectomy program: eligibility and safety evaluation. Surgery. 2012;152:1133–41.PubMedCrossRef
8.
Carter Y, Chen H, Sippel RS. An intact parathyroid hormone-based protocol for the prevention and treatment of symptomatic hypocalcemia after thyroidectomy. J Surg Res. 2014;186:23–8.PubMedCrossRef
9.
Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97:4549–58.PubMedCrossRef
10.
BahnChair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646.PubMedCrossRef
11.
Yamashita H, Noguchi S, Murakami T, et al. Predictive risk factors for postoperative tetany in female patients with Graves’ disease. J Am Coll Surg. 2001;192:465–8.PubMedCrossRef
12.
Pesce CE, Shiue Z, Tsai HL, et al. Postoperative hypocalcemia after thyroidectomy for Graves’ disease. Thyroid. 2010;20:1279–83.PubMedCrossRef
13.
Welch KC, McHenry CR. Total thyroidectomy: is morbidity higher for Graves’ disease than nontoxic goiter? J Surg Res. 2011;170:96–9.PubMedCrossRef
14.
Snyder S, Govednik C, Lairmore T, Jiang DS, Song J. Total thyroidectomy as primary definitive treatment for Graves’ hyperthyroidism. Am Surg. 2013;79:1283–8.PubMed
15.
Kisakol G, Kaya A, Gonen S, Tunc R. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J. 2003;50:657–61.PubMedCrossRef
16.
Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves’ disease? Thyroid. 2005;15:569–74.PubMedCrossRef
17.
Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States. World J Surg. 2010;34:1261–4.PubMedCrossRef
18.
Murray SE, Sippel RS, Chen H. Incidence of concomitant hyperparathyroidism in patients with thyroid disease requiring surgery. J Surg Res. 2012;178:264–7.PubMedCentralPubMedCrossRef
19.
Langley RW, Burch HB. Perioperative management of the thyrotoxic patient. Endocrinol Metab Clin North Am. 2003;32:519–34.PubMedCrossRef
20.
Yamashita H, Noguchi S, Murakami T, et al. Calcium and its regulating hormones in patients with Graves’ disease: sex differences and relation to postoperative tetany. Eur J Surg. 2000;166:924–8.PubMedCrossRef
21.
Thomusch O, Machens A, Sekulla C, et al. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg. 2000;24:1335–41.PubMedCrossRef
22.
Rafferty MA, Goldstein DP, Rotstein L, et al. Completion thyroidectomy versus total thyroidectomy: is there a difference in complication rates? An analysis of 350 patients. J Am Coll Surg. 2007;205:602–7.PubMedCrossRef
23.
Erbil Y, Ozluk Y, Giris M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab. 2007;92:2182–9.PubMedCrossRef
24.
Shinall MC, Jr., Broome JT, Baker A, Solorzano CC. Is potassium iodide solution necessary before total thyroidectomy for Graves’ disease? Ann Surg Oncol. 2013;20:2964–7.PubMedCrossRef
25.
In H, Pearce EN, Wong AK, Burgess JF, McAneny DB, Rosen JE. Treatment options for Graves’ disease: a cost-effectiveness analysis. J Am Coll Surg. 2009;209:170–9.e171–2.
26.
Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy: a safe and effective treatment for Graves’ disease. J Surg Res. 2011;168:1–4.PubMedCentralPubMedCrossRef
27.
Yip J, Lang BH, Lo CY. Changing trend in surgical indication and management for Graves’ disease. Am J Surg. 2012;203:162–7.PubMedCrossRef
28.
Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Ann Surg Oncol. 2013;20:660–7.PubMedCrossRef
29.
Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2002;87:1073–7.PubMed
30.
Torring O, Tallstedt L, Wallin G, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine—a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab. 1996;81:2986–93.PubMed
31.
Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009;19:559–63.PubMedCrossRef
32.
Ljunggren JG, Torring O, Wallin G, et al. Quality of life aspects and costs in treatment of Graves’ hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid. 1998;8:653–9.PubMedCrossRef
33.
Stavrakis AI, Ituarte PH, Ko CY, Yeh MW. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery. 2007;142:887–99.PubMedCrossRef
34.
Oltmann SC, Schneider DF, Leverson G, Sivashanmugam T, Chen H, Sippel RS. Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation. Ann Surg Oncol. 2014;21:1379–83.PubMedCentralPubMedCrossRef
35.
Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228:320–30.PubMedCentralPubMedCrossRef
Metadata
Title
Preventing Postoperative Hypocalcemia in Patients with Graves Disease: A Prospective Study
Authors
Sarah C. Oltmann, MD
Andrew V. Brekke
David F. Schneider, MD, MS
Sarah C. Schaefer, ANP-BC
Herbert Chen, MD
Rebecca S. Sippel, MD
Publication date
01-03-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 3/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4077-8

Other articles of this Issue 3/2015

Annals of Surgical Oncology 3/2015 Go to the issue

Hepatobiliary Tumors

Yttrium-90 Radioembolization is a Viable Treatment Option for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases: Further Evidence in Support of a New Treatment Paradigm

Bone and Soft Tissue Sarcomas

Secondary Malignant Neoplasms after Osteosarcoma: Early Onset and Cumulative Alkylating Agent Dose Dependency

Hepatobiliary Tumors

Lymph Node Metastases in Patients Undergoing Surgery for a Gallbladder Cancer. Extension of the Lymph Node Dissection and Prognostic Value of the Lymph Node Ratio

Gastrointestinal Oncology

Increase in Peritoneal Recurrence Induced by Intraoperative Hemorrhage in Gastrectomy

Breast Oncology

Global Surgical Oncology Disease Burden: Addressing Disparities Via Global Surgery Initiatives: The University of Michigan International Breast Cancer Registry

Bone and Soft Tissue Sarcomas

Percutaneous Core Needle Biopsy in Retroperitoneal Sarcomas Does Not Influence Local Recurrence or Overall Survival